EMAIL THIS PAGE TO A FRIEND

Life sciences

Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats.


PMID 26612350

Abstract

In this study, we investigated the effects of Bax-inhibiting peptide (Bip)-V5, an anti-apoptosis membrane-permeable peptide, on the 6-hydroxydopamine (6-OHDA) induced Parkinson's disease (PD) model rats. Rats were randomly divided into five groups: Control, 6-OHDA only, Vehicle+6-OHDA, zVAD+6-OHDA, and V5+6-OHDA, that rats were preadministrated with different reagents before 6-OHDA administration. The result showed that intrastriatal preadministration of Bip-V5 significantly decreased the amphetamine-induced rotation of the 6-OHDA model rats and the loss of the nigral dopaminergic (DA) neurons. Moreover, Bip-V5 intrastriatal preadministration not only significantly decreased the expression of activated caspase 9 and activated caspase 3 but also decreased the enhanced expression of AIF and its nuclear translocation in the SNpc. The results in our study provide the first experimental evidence that both caspase-dependent and AIF-dependent apoptosis pathways are involved in the loss of the nigral DA neurons caused by intrastriatal administration of 6-OHDA, and intrastriatal preadministration of Bip-V5 can inhibit the above two apoptosis pathways to protect the nigral DA neurons. Our results provide a new idea that Bax-inhibiting peptide may be a promising preventive or therapeutic method for PD.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H4381
6-Hydroxydopamine hydrochloride, ≥97% (titration), powder
C8H11NO3 · HCl